Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder

NCT: NCT06142955 · RECRUITING

NCT IDNCT06142955
StatusRECRUITING
Start Date2024-04-30
Completion2027-02
SponsorYale University (OTHER)
First posted
Last updated

Brief Summary

This study will assess clinical and behavioral measures along with electroencephalogram (EEG), event-related potentials (ERPS), and eye-tracking (ET) prior to and following a single intermittent Theta Burst Stimulation (iTBS) session to provide preliminary insight into the potential of TMS as an intervention for depression in individuals with Autism Spectrum Disorder (ASD).

Frequently Asked Questions

What is Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder?

Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder is a clinical trial registered under NCT06142955. Current status: RECRUITING.

What is the status of NCT06142955?

The current status of NCT06142955 (Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder) is: RECRUITING.

When did Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder start?

Transcranial Magnetic Stimulation (TMS) to Treat Depression in Autism Spectrum Disorder started on 2024-04-30.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑